Survival impact of adjuvant treatment in resected stage III cutaneous melanoma patients: Results from a real-life cohort study (TAMARIS).
Charlée Nardin(CHU Dijon Bourgogne), O. Zehou, P. Celérier(Centre Hospitalier de La Rochelle), Philippe Bernard(Hôpital Dupuytren), G. Jeudy(CHU Dijon Bourgogne), Henri Montaudié(Hôpital l'Archet), F. Aubin(Centre Hospitalier Universitaire de Besançon), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Florent Grange(Hôpital Lyon Sud), C. Lesage(Université de Montpellier), J. Charles(Apple (Israel)), G. Quéreux(Nantes Université), Théo Erard(Centre Hospitalier Universitaire de Besançon), Marc Puyraveau(Inserm), Amir Khammari(Inserm), M. Amini Adle(Centre Léon Bérard)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Tests of general relativity with binary black holes from the second LIGO-Virgo gravitational-wave transient catalog
|Physical review. D/Physical review. D.|2021|795